Cannabis as Medicine

Does marijuana affect ADHD?

In a study of 268 separate online discussion threads, 25 percent of people said they believed that marijuana was useful. The researchers point out, however, that research proving a connection between marijuana and positive therapeutic outcomes is limited. Other limited studies have suggested that marijuana would improve cognitive ability and impulse control, so it may

Does marijuana affect ADHD? Read More »

American Epilepsy Society’s Letter On Marijuana And CBD 2016

EXCERPT:  “The families and children coming to Colorado are receiving unregulated, highly variable artisanal preparations of cannabis oil prescribed, in most cases, by physicians with no training in pediatrics, neurology or epilepsy. As a result, the epilepsy specialists in Colorado have been at the bedside of children having severe dystonic reactions and other movement disorders,

American Epilepsy Society’s Letter On Marijuana And CBD 2016 Read More »

The Medical Letter on Drugs and Therapeutics : Cannabis and Cannabinoids

The cannabinoids dronabinol (Marinol, and generics) and nabilone (Cesamet) are effectivefor treatment of chemotherapy-induced nausea and vomiting, for which they have been approved in the US. Cannabinoid products may also be effective for second-line treatment of cancer pain and the neuropathic pain and spasticity of multiple sclerosis, but none are currently approved for these indications.

The Medical Letter on Drugs and Therapeutics : Cannabis and Cannabinoids Read More »

Marijuana: Could it slow Parkinson’s Disease Progression?

Written by Marie Ellis Published: Friday 9 December 2016 Parkinson’s disease is the second most common neurological illness in the United States, causing tremors, slowness of movement, postural instability, and impaired balance and coordination. But findings from a new review suggest symptoms of the condition could be improved with marijuana. A new review suggests medical

Marijuana: Could it slow Parkinson’s Disease Progression? Read More »

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome

At the 70th annual meeting of the American Epilepsy Society in Houston this week, GW Pharmaceuticals announced results of the first ever randomized, double-blind, placebo-controlled studies of CBD. The company’s proprietary CBD drug is called Epidiolex. In the Dravet syndrome study, 43 percent of patients taking Epidiolex had a greater than or equal to 50 percent

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome Read More »

THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy:

Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol José A. S. Crippa1*, Ana C. S. Crippa2, Jaime E. C. Hallak1, Rocio Martín-Santos1,3and Antonio W. Zuardi1 1Department of Neuroscience and Behavior, University of São Paulo, Ribeirão Preto, Brazil 2Department of Clinical Medicine, Federal University of

THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Read More »

Scroll to Top